What is the point of biosimilars and the promise of lower prices if the only beneficiary is the government's economic interest? Oh wait. The government's economic interest is the only consideration in Australia's HTA system.
A good idea that will need to overcome an institutional mindset
February 19, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Medicines Australia chief says next negotiation is about getting comfortable with being uncomfortable
July 3, 2026 - - Latest News -
New once weekly therapy offers extended protection for people with haemophilia A
July 3, 2026 - - Latest News -
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Nothing else grows below this self-serving and broken institutional framework
July 3, 2026 - - Latest News -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News

